Search Press releases Keywords From To 7 Mar 2025 BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis Read More 7 Mar 2025 BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden Read More 27 Feb 2025 On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth Read More 12 Feb 2025 BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) Read More 31 Jan 2025 RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods Read More 15 Jan 2025 UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 2 of 66 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
